Comparative Pharmacology
Head-to-head clinical analysis: MIEBO versus VEVYE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIEBO versus VEVYE.
MIEBO vs VEVYE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MIEBO (perfluorohexyloctane) is a semifluorinated alkane that forms a protective lipid layer on the ocular surface, reducing tear evaporation and improving tear film stability. It also acts as a lubricant.
Vevye (cyclosporine ophthalmic solution) is a calcineurin inhibitor immunosuppressant. It inhibits T-cell activation by binding to cyclophilin, forming a complex that blocks calcineurin, thereby preventing dephosphorylation and nuclear translocation of nuclear factor of activated T-cells (NFAT), reducing pro-inflammatory cytokine production (e.g., IL-2). In ocular tissues, it suppresses inflammation and immune-mediated responses, increasing tear production through anti-inflammatory effects on lacrimal glands.
Not applicable. MIEBO (perfluorohexyloctane) is an ophthalmic emulsion; one drop in each eye four times daily.
VEVYE (voclosporin) 23.7 mg orally twice daily in combination with mycophenolate mofetil and corticosteroids.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours; clinically relevant for once-daily dosing.
Terminal elimination half-life: 12-15 hours in healthy adults; prolonged to 24-30 hours in renal impairment (CrCl <30 mL/min)
Primarily renal excretion of unchanged drug (approximately 60-70%) and hepatic metabolism with biliary/fecal elimination (30-40%).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Ophthalmic Lubricant
Ophthalmic Lubricant